Načítá se...
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevent...
Uloženo v:
| Vydáno v: | J Lipid Atheroscler |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Korean Society of Lipidology and Atherosclerosis
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7379114/ https://ncbi.nlm.nih.gov/pubmed/32821708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12997/jla.2019.8.2.183 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|